Halozyme Q4 revenue falls
Halozyme has posted net loss of $16.89m, compared to a net loss of $12.66m, for the same period in 2009. The company’s operating loss was $17.88m for the
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
The multicentre, randomized, double-masked, sham injection-controlled, 36-month trial involved 377 patients with DME, who were randomised to receive monthly injections of either 0.3mg Lucentis (n=125), 0.5mg Lucentis (n=125)